EVOLVE试验中血液透析患者的血清睾酮浓度与结局
基于EVOLVE试验中1692例男性和1059例女性的血液透析患者数据,分析总睾酮、游离睾酮和性激素结合球蛋白(SHBG)与死亡及主要心血管事件的关联。男性中较低游离睾酮和较高SHBG与死亡或心血管事件风险升高相关,女性中无此关联;西那卡塞治疗对睾酮浓度无显著影响。
要点
- 男性血液透析患者中,较低游离睾酮与死亡或心血管事件风险升高相关。
- 男性中较高SHBG与全因死亡率升高相关,总睾酮无显著关联。
- 女性中总睾酮、游离睾酮及SHBG均与结局无显著关联。
核心结论
- 男性慢性血液透析患者中,较低血清游离睾酮和较高SHBG与死亡或心血管事件风险升高相关。
研究设计与样本
- 基于随机对照EVOLVE试验(西那卡塞治疗降低心血管事件评估)的数据分析,纳入1692例男性和1059例女性血液透析患者。
主要发现
- 男性中,较低血清游离睾酮与死亡或心血管事件风险升高相关(OR 0.18,95%CI 0.04-0.82,P=0.026)。
- 男性中,较高SHBG与死亡或心血管事件风险升高相关(每10 nmol/L OR 1.05,95%CI 1.01-1.10,P=0.012)。
- 男性中,仅SHBG与全因死亡率相关(每10 nmol/L OR 1.07,95%CI 1.02-1.12,P=0.0073)。
- 女性中,总睾酮、游离睾酮及SHBG均与结局无显著关联。
- 西那卡塞治疗对SHBG、游离睾酮或总睾酮无统计学显著影响。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypogonadism is common in end-stage kidney disease and may contribute to morbidity and mortality. METHODS: Using data from the randomized controlled Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE) trial of cinacalcet, we analyzed the associations of total testosterone, free testosterone and sex hormone-binding globulin (SHBG) serum concentrations with mortality and major cardiovascular events in 1692 men and 1059 women receiving hemodialysis. We also describe the effect of cinacalcet treatment on serum concentrations of testosterone. RESULTS: Among men, lower serum free testosterone [odds ratio (OR) 0.18, 95% confidence interval (CI) 0.04-0.82, P = .026] and higher SHBG (OR 1.05 per 10 nmol/L, 95% CI 1.01-1.10, P = .012), but not total testosterone, were associated with higher risk of death or cardiovascular event. Only SHBG was associated with all-cause mortality (OR 1.07 per 10 nmol/L, 95% CI 1.02-1.12, P = .0073). Among women, neither total nor free testosterone, nor SHBG were associated with outcomes. We found no statistically significant effect of cinacalcet treatment on SHBG, free or total testosterone. CONCLUSIONS: Lower free testosterone and higher SHBG in serum are associated with higher risk of death or cardiovascular event in men undergoing chronic hemodialysis.
引用
- Nilsson E, Stenvinkel P, Liu S, et al. Serum testosterone concentrations and outcomes in hemodialysis patients enrolled in the EVOLVE trial. Nephrol Dial Transplant. 2023. PMID: 36175142. doi:10.1093/ndt/gfac278
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。